TY - T1的CGRP怎样抑制tev - 48125对心血管的影响参数的函数曲普坦使用个体慢性偏头痛(P2.205) JF -神经学乔-神经学六世- 86 - 16补充SP - P2.205盟朱莉安娜VanderPluym AU - David Dodick盟马塞洛Bigal Y1 - 2016/04/05 UR - http://首页www.ez-admanager.com/content/86/16_Supplement/P2.205.abstract N2 -目的:评价tev - 48125对心血管的影响参数的函数曲普坦使用。背景:tev - 48125是一种单克隆抗体对降钙素相关基因肽(CGRP怎样)证明是有效的和可容忍的慢性偏头痛的预防治疗试验(CM)。CGRP怎样是一个强有力的系统性血管舒张,因此有人担心潜在的心血管效应的抑制。此外,有人担心潜在的心血管影响合并施打CGRP怎样拮抗剂的药物,这是已知vasoconstrictive药物。方法:目前的研究代表了因果分析2 b阶段试验的一部分进行的。double-dummy多中心,随机,双盲,安慰剂对照,与这些相应平行的组织研究测试每月一次注射tev - 48125 675/225毫克或900毫克,或安慰剂。参与者被男性或女性与CM 18岁到65岁。收缩压(SBP)、舒张压(菲律宾)、心率(HR)测定在预先确定的访问。曲普坦消费信息获得每日在基线阶段和持续时间的研究。参与者并不局限在他们曲普坦消费。 Results: In the overall sample (n=264), there were no relevant changes in blood pressure or other vital signs. SBP, DBP, and HR were similar regardless of the level of triptan use. The mean values of SBP, DBP, and HR at the end of study, when participants had received three months of CGRP inhibition via TEV-48125, remained similar. Conclusions: Inhibition of CGRP withTEV-48125 was not associated with hemodynamic changes among individuals with CM using triptans in the context of a 3-month study. This is an important finding given the concerns surrounding potential cardiovascular effects of CGRP inhibition, particularly in the setting of other vasoconstrictive medications like triptans. Study Supported by: Teva Pharmaceuticals, Netanya IsraelDisclosure: Dr. VanderPluym has nothing to disclose. Dr. Dodick has received personal compensation for activities with Allergan, Amgen, Alder, Merck Serono, ENeuro, Eli Lilly, Autonomic Technologies, Boston Scientific, Novartis, Tonix, Teva, Trigemina as a consultant and for activities with SAGE Publishing, Dr. Bigal holds stock and/or stock option in Teva which sponsored research in which Dr. Bigal was involved as an investigator.Sunday, April 17 2016, 8:30 am-5:30 pm ER -